Drug intelligence / Profile preview

MZ-302

Development stage: Preclinical
Lead developer: Maze Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

MZ-302 is a specific inhibitor of Apolipoprotein-L1 (APOL1). It has been shown to reverse the activation, proliferation, and central memory (Tcm) expansion of G1-BAC-Tg-CD8+T-cells after ex-vivo T-cell receptor (TCR) stimulation. This action suggests its potential in modulating T-cell intrinsic mechanisms associated with APOL1 exonic variants, which are linked to kidney rejection.

Targets

APOL1 (Apolipoprotein L1)

Beyond the preview

Go deeper on MZ-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MZ-302.

Explore the full profile